Clinical trials: Hepatitis C Virus
Hepatitis C, Chronic
Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)
This is a randomized, open-label, multinational study designed to evaluate the "standard" regimen, PegIntron 1.5 µg/kg subcutaneously once weekly plus ribavirin 800-1200 mg daily [Arm PEG2b 1.5/R (24 weeks)], compared to a lower…
- Trial name
- NCT00302081
- Testing
- peginterferon alfa-2b (SCH 54031), ribavirin (SCH 18908)
- Volunteers
- 696 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.
GSK2878175 is a site IV NS5B non-nucleoside inhibitor (NNI) being developed for the treatment of chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT02014571
- Testing
- GSK2878175
- Where
- Puerto Rico
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Liver Fibrosis, Hepatic Fibrosis
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
This is a double-blind, multicenter study involving patients with chronic HCV infection who had a liver transplantation; developed HCV-related liver fibrosis and/or incomplete cirrhosis; achieved a sustained virologic response…
- Conditions
- Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
- Trial name
- POLT-HCV-SVR (NCT02138253)
- Testing
- IDN-6556
- Where
- 35 sites in United States
- Volunteers
- 64 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Hepatitis C Virus
An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection
The purpose of this study is to describe the genetic diversity of Hepatitis C virus (HCV) NS3/4a protease and NS5A protein of HCV in participants with chronic disease naive-drug or previously failed to double therapy…
- Trial name
- MAPPING (NCT02597270)
- Where
- 6 sites in Brazil
- Volunteers
- 239 people
- Sponsor
- Janssen-Cilag Ltd.
Chronic Hepatitis C
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)
This is a 2-part study. The purpose of Part A is to assess the efficacy and safety of grazoprevir (MK-5172) 100 mg in combination with elbasvir (MK-8742) 50 mg for 12 weeks in the treatment of chronic HCV GT1, GT4, or GT6…
- Trial name
- C-EDGE CO-STAR (NCT02105688)
- Testing
- Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
- Volunteers
- 301 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
- Trial name
- NCT00336479
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 263 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Sequelae of Viral Hepatitis, Transplantation Infection
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
A Phase 2 study to evaluate safety, pharmacokinetics and efficacy of Hepatitis C Immune Globulin Intravenous (human) [Civacir(TM)] for preventing or reducing the impact of recurrent HCV infection following liver transplantation.
- Conditions
- Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation
- Trial name
- NCT00473824
- Testing
- Hepatitis C Immune Globulin Intravenous (Human) 5%
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- ADMA Biologics, Inc.
Chronic Hepatitis c
Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C
This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin（RBV） in the treatment of Chronic…
- Trial name
- NCT01903278
- Testing
- PEG-IFN-SA /RBV, Pegasys /RBV
- Where
- 41 sites in China
- Volunteers
- 719 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Hepatitis C Virus Infection
Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study
The primary objective of this study is to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (Epclusa®; SOF/VEL) with ribavirin (RBV) for 24 weeks in adults with chronic hepatitis C virus…
- Trial name
- NCT02300103
- Testing
- SOF/VEL, RBV
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 69 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo
The purpose of this study is to provide access to telaprevir for patients from the control group in the C216 study, who failed treatment for virologic reasons.
- Trial name
- NCT01054573
- Testing
- Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
- Where
- 48 sites in United States, Australia and 13 more
- Volunteers
- 90 people
- Sponsor
- Janssen Infectious Diseases BVBA
Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
Eltrombopag Phase III Study In Chinese Chronic ITP Patients
This randomized, double-blind and open-label phase III study aimed to determine the efficacy, tolerance and safety of eltrombopag in Chinese chronic primary immune thrombocytopenia (ITP) adult subjects.
- Trial name
- NCT01762761
- Testing
- eltrombopag
- Where
- 18 sites in China
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C Virus Infection
Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients
The purpose of this study is to evaluate if the DNA vaccine CHRONVAC-C® intended for future treatment of Hepatitis C infections is safe and tolerated when administered to HCV infected individuals with a low viral load.
- Trial name
- NCT00563173
- Testing
- CHRONVAC-C®
- Where
- 2 sites in Sweden
- Volunteers
- 12 people
- Sponsor
- Tripep AB
Chronic Hepatitis C
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.
The purpose of the study was to determine safety and efficacy of 48 weeks treatment with Thymosin alpha 1 (Talpha1) in combination with pegylated interferon (PEGIFN) alpha2a and ribavirin (RBV) in adult patients with chronic…
- Trial name
- NCT01178996
- Testing
- Thymosin alpha 1, Ribavirin, PEGinterferon alfa2a
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 552 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Chronic Hepatitis C
Clinical Pharmacology Study of MP-424
To conduct the following evaluations in Korean healthy male adult volunteers receiving a single and multiple doses of MP-424 tablets: Pharmacokinetics of MP-424 after a single and multiple doses.
- Trial name
- NCT01766167
- Testing
- MP-424
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) in participants with chronic genotype 1, 2, 4, 6 or indeterminate HCV infection who…
- Trial name
- NCT02346721
- Testing
- SOF/VEL
- Where
- 61 sites in United States, Belgium and 7 more
- Volunteers
- 111 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
This study aims to evaluate whether an investigational monoclonal antibody, CT-011, is safe to give and if it helps patients with hepatitis C virus (HCV).
- Trial name
- NCT00962936
- Testing
- CT-011
- Where
- Israel
- Volunteers
- 13 people
- Sponsor
- CureTech Ltd
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.
Hepatitis C
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.
- Trial name
- NCT00780416
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 189 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV…
- Trial name
- NCT00420784
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a
- Where
- 53 sites in United States, Canada and 3 more
- Volunteers
- 465 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C
The objective of this trial is to investigate tolerability, safety, pharmacokinetics and antiviral activity of BI 207127 NA in combination with BI 201335 NA and ribavirin for 8 weeks in Japanese treatment-naive patients with…
- Trial name
- NCT01528735
- Testing
- BI 207127 NA, peginterferon, Ribavirin
- Where
- 5 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.